<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>WHO</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Latest benchmark shows 35% decline in antibiotics pipeline in past 5 years</title>
      <description>
        <![CDATA[Twelve years on from the World Health Organization formally raising the alarm, antimicrobial resistance continues to grow, and despite numerous public and private incentives and initiatives, the pipeline of antibiotics in development is thinner than ever.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729454</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729454-latest-benchmark-shows-35-decline-in-antibiotics-pipeline-in-past-5-years</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-capsules-and-petri-dish.webp?t=1622745909" type="image/png" medium="image" fileSize="423462">
        <media:title type="plain">Drug capsules in petri dish</media:title>
      </media:content>
    </item>
    <item>
      <title>US completes withdrawal from WHO</title>
      <description>
        <![CDATA[It’s official. A year after President Donald Trump issued an order requiring the U.S. to withdraw from the World Health Organization (WHO), that withdrawal has been completed.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/728174</guid>
      <pubDate>Fri, 23 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728174-us-completes-withdrawal-from-who</link>
    </item>
    <item>
      <title>With malaria numbers rising, Novartis has phase III success</title>
      <description>
        <![CDATA[Phase III data from Novartis AG for the malaria treatment Ganlum (KLU-156) show it met the primary endpoint of noninferiority to the current standard of care, Coartem, a combination of artemether and lumefantrine. The results are a step to curbing a problem that has seen rising numbers in recent years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726159</guid>
      <pubDate>Thu, 13 Nov 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726159-with-malaria-numbers-rising-novartis-has-phase-iii-success</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Mosquito-on-skin.webp?t=1763072771" type="image/jpeg" medium="image" fileSize="668288">
        <media:title type="plain">Mosquito </media:title>
      </media:content>
    </item>
    <item>
      <title>Drug resistance rising: one in six infections show no response</title>
      <description>
        <![CDATA[One in six common bacterial infections diagnosed worldwide in 2023 were resistant to treatment with antibiotics, according to the latest surveillance data gathered by the World Health Organization (WHO). Drug-resistant gram-negative bacteria that cause bloodstream infections that can lead to sepsis, organ failure and death are an increasing threat globally.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725002</guid>
      <pubDate>Mon, 13 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725002-drug-resistance-rising-one-in-six-infections-show-no-response</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/bacteria-culture-drug-resistance-petri-dish-lab.webp?t=1741103935" type="image/jpeg" medium="image" fileSize="160105">
        <media:title type="plain">Art concept for antimicrobial research</media:title>
      </media:content>
    </item>
    <item>
      <title>KDCA readies mRNA vaccines, tech for COVID-19, future outbreaks</title>
      <description>
        <![CDATA[Korea Disease Control and Prevention Agency (KDCA) secured 5.3 million doses of COVID-19 vaccines made by Pfizer Inc./Biontech SE and Moderna Inc., officially including the mRNA-based vaccines in the country’s national immunization program on Aug. 5.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723012</guid>
      <pubDate>Tue, 12 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723012-kdca-readies-mrna-vaccines-tech-for-covid-19-future-outbreaks</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/mRNA-vaccine-vials-syringe.webp?t=1605563411" type="image/png" medium="image" fileSize="411474">
        <media:title type="plain">COVID-19 mRNA vaccine vials, syringe</media:title>
      </media:content>
    </item>
    <item>
      <title>Self-amplifying mRNA technology underscored for next big pandemic</title>
      <description>
        <![CDATA[Experts in mRNA convened at the Global Vaccine Forum (GVF) 2025 to weigh the present and future of vaccine technology, including emerging innovations in self-amplifying mRNA (sa-mRNA) and drug delivery platforms. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/721835</guid>
      <pubDate>Tue, 01 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721835-self-amplifying-mrna-technology-underscored-for-next-big-pandemic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Vaccineforum-IVI-directorgeneral-Jerome-KIM-6-27-hero.webp?t=1751053811" type="image/jpeg" medium="image" fileSize="538538">
        <media:title type="plain">Jerome Kim, of IVI, speaking at the Global Vaccine Forum</media:title>
        <media:description type="plain">Jerome Kim, director-general, IVI</media:description>
      </media:content>
    </item>
    <item>
      <title>Self-amplifying mRNA technology underscored for next big pandemic</title>
      <description>
        <![CDATA[Experts in mRNA convened at the Global Vaccine Forum (GVF) 2025 to weigh the present and future of vaccine technology, including emerging innovations in self-amplifying mRNA (sa-mRNA) and drug delivery platforms. “Breakthroughs in mRNA and next-generation vaccine platforms are revolutionizing how we prepare for and respond to global health challenges,” Jerome H. Kim, International Vaccine Institute (IVI) director general, told the audience in Seoul, South Korea, June 19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721529</guid>
      <pubDate>Fri, 27 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721529-self-amplifying-mrna-technology-underscored-for-next-big-pandemic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Vaccineforum-IVI-directorgeneral-Jerome-KIM-6-27-hero.webp?t=1751053811" type="image/jpeg" medium="image" fileSize="538538">
        <media:title type="plain">Jerome Kim, of IVI, speaking at the Global Vaccine Forum</media:title>
        <media:description type="plain">Jerome Kim, director-general, IVI</media:description>
      </media:content>
    </item>
    <item>
      <title>WHO member states outline pandemic plan</title>
      <description>
        <![CDATA[After more than three years of discussion, the World Health Organization’s Intergovernmental Negotiating Body (INB) has agreed on a proposal to prevent, prepare and respond to a pandemic. The plan is born, the INB proposal said, out of inequities around the world that slowed timely and equitable access to health products to respond to the COVID-19 pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719567</guid>
      <pubDate>Tue, 22 Apr 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719567-who-member-states-outline-pandemic-plan</link>
    </item>
    <item>
      <title>WHO member states outline pandemic plan</title>
      <description>
        <![CDATA[After more than three years of discussion, the World Health Organization’s Intergovernmental Negotiating Body (INB) has agreed on a proposal to prevent, prepare and respond to a pandemic. The plan is born, the INB proposal said, out of inequities around the world that slowed timely and equitable access to health products to respond to the COVID-19 pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719452</guid>
      <pubDate>Thu, 17 Apr 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719452-who-member-states-outline-pandemic-plan</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/global-disease-health-infection.webp?t=1589309549" type="image/png" medium="image" fileSize="253341">
        <media:title type="plain">Gloved hand holding petri dish containing world map</media:title>
      </media:content>
    </item>
    <item>
      <title>WHO member states outline pandemic plan</title>
      <description>
        <![CDATA[After more than three years of discussion, the World Health Organization’s Intergovernmental Negotiating Body (INB) has agreed on a proposal to prevent, prepare and respond to a pandemic. The plan is born, the INB proposal said, out of inequities around the world that slowed timely and equitable access to health products to respond to the COVID-19 pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719291</guid>
      <pubDate>Wed, 16 Apr 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719291-who-member-states-outline-pandemic-plan</link>
    </item>
    <item>
      <title>WHO looking to fill funding gap left by the US</title>
      <description>
        <![CDATA[The U.S. foreign aid cuts and freezes that are taking place under President Donald Trump are putting at risk the global public health gains that have been made against diseases such as malaria, HIV and tuberculosis over the past two decades, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus said at a March 17 media briefing, as he called on other countries to step up and fill the gap.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718369</guid>
      <pubDate>Tue, 18 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718369-who-looking-to-fill-funding-gap-left-by-the-us</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/WHO-headquarters.webp?t=1632869746" type="image/png" medium="image" fileSize="673912">
        <media:title type="plain">WHO headquarters, Geneva</media:title>
        <media:description type="plain">WHO headquarters in Geneva. Credit: diegograndi - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Mum’s the word at US health agencies awaiting new leadership</title>
      <description>
        <![CDATA[With key officials yet to be confirmed at the U.S. Department of Health and Human Services, the acting secretary imposed an immediate pause throughout the department on publicly issuing any document or communication without first getting it approved by a presidential appointee.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716582</guid>
      <pubDate>Thu, 23 Jan 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716582-mums-the-word-at-us-health-agencies-awaiting-new-leadership</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/US-flag-and-HHS-logo.webp?t=1741041163" type="image/jpeg" medium="image" fileSize="372904">
        <media:title type="plain">US flag and HHS logo</media:title>
        <media:description type="plain">Credit: mehaniq41</media:description>
      </media:content>
    </item>
    <item>
      <title>Stocks rise along with concerns of global mpox outbreak</title>
      <description>
        <![CDATA[Following the World Health Organization’s escalation of mpox to a public health emergency of international concern on Aug. 14 and the emergence of what appears to be a more severe strain of the orthopoxvirus, the spotlight has focused on a handful of companies working on vaccines and antivirals. Shares of Geovax Labs Inc., Emergent Biosolutions Inc. and Tonix Pharmaceuticals Inc. were all trading up Aug. 19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711915</guid>
      <pubDate>Tue, 27 Aug 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711915-stocks-rise-along-with-concerns-of-global-mpox-outbreak</link>
    </item>
    <item>
      <title>Stocks rise along with concerns of global mpox outbreak</title>
      <description>
        <![CDATA[Following the World Health Organization’s escalation of mpox to a public health emergency of international concern on Aug. 14 and the emergence of what appears to be a more severe strain of the orthopoxvirus, the spotlight has focused on a handful of companies working on vaccines and antivirals. Shares of Geovax Labs Inc., Emergent Biosolutions Inc. and Tonix Pharmaceuticals Inc. were all trading up Aug. 19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711731</guid>
      <pubDate>Tue, 20 Aug 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711731-stocks-rise-along-with-concerns-of-global-mpox-outbreak</link>
    </item>
    <item>
      <title>Stocks rise along with concerns of global mpox outbreak</title>
      <description>
        <![CDATA[Following the World Health Organization’s escalation of mpox to a public health emergency of international concern on Aug. 14 and the emergence of what appears to be a more severe strain of the orthopoxvirus, the spotlight has focused on a handful of companies working on vaccines and antivirals. Shares of Geovax Labs Inc., Emergent Biosolutions Inc. and Tonix Pharmaceuticals Inc. were all trading up Aug. 19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711697</guid>
      <pubDate>Mon, 19 Aug 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711697-stocks-rise-along-with-concerns-of-global-mpox-outbreak</link>
    </item>
    <item>
      <title>WHO preps for human avian flu spread with mRNA vaccine project</title>
      <description>
        <![CDATA[With the COVID-19 pandemic still visible in the rearview mirror, the World Health Organization (WHO) is taking no chances as it preps for human avian influenza, or H5N1, a subtype of influenza A. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/710801</guid>
      <pubDate>Tue, 30 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710801-who-preps-for-human-avian-flu-spread-with-mrna-vaccine-project</link>
    </item>
    <item>
      <title>World Health Assembly extends deadline for pandemic agreement</title>
      <description>
        <![CDATA[Although consensus was not reached on the World Health Organization’s pandemic agreement, the World Health Assembly recognized the progress made by member states to develop a pandemic agreement and to strengthen International Health Regulations (IHR, 2005) during the 77th World Health Assembly meeting held May 27 to June 1 in Geneva.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709204</guid>
      <pubDate>Tue, 04 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709204-world-health-assembly-extends-deadline-for-pandemic-agreement</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/coronavirus-COVID-19-globe.webp?t=1745261241" type="image/jpeg" medium="image" fileSize="352314">
        <media:title type="plain">Earth threatened by virus</media:title>
      </media:content>
    </item>
    <item>
      <title>Sanders pressures international industry to back Pandemic Accord</title>
      <description>
        <![CDATA[Looking beyond the U.S. biopharma industry, Sen. Bernie Sanders (I-Vt.) is now pushing the International Federation of Pharmaceutical Manufacturers and Associations to get on board with the World Health Organization’s proposed Pandemic Accord aimed at making diagnostics, treatments and vaccines available to everyone who needs them.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708118</guid>
      <pubDate>Tue, 30 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708118-sanders-pressures-international-industry-to-back-pandemic-accord</link>
    </item>
    <item>
      <title>WHO pandemic deal doesn’t protect developing countries, groups say</title>
      <description>
        <![CDATA[The latest World Health Organization’s (WHO) Pandemic Agreement falls short of protecting all countries in future pandemics, said international patient groups and public health organizations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708106</guid>
      <pubDate>Tue, 30 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708106-who-pandemic-deal-doesnt-protect-developing-countries-groups-say</link>
    </item>
    <item>
      <title>Sanders pressures international industry to back Pandemic Accord</title>
      <description>
        <![CDATA[Looking beyond the U.S. biopharma industry, Sen. Bernie Sanders (I-Vt.) is now pushing the International Federation of Pharmaceutical Manufacturers and Associations to get on board with the World Health Organization’s proposed Pandemic Accord aimed at making diagnostics, treatments and vaccines available to everyone who needs them.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708077</guid>
      <pubDate>Mon, 29 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708077-sanders-pressures-international-industry-to-back-pandemic-accord</link>
    </item>
    <item>
      <title>Eubiologics wins WHO prequalification for oral cholera vaccine</title>
      <description>
        <![CDATA[South Korea’s Eubiologics Co. Ltd. said it gained the World Health Organization’s (WHO) prequalification designation on April 16 for its simplified oral cholera vaccine, approved as Euvichol-S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/707534</guid>
      <pubDate>Tue, 16 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707534-eubiologics-wins-who-prequalification-for-oral-cholera-vaccine</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Euvichol-4-16.webp?t=1713290925" type="image/jpeg" medium="image" fileSize="81505">
        <media:title type="plain">Euvichol</media:title>
        <media:description type="plain">Credit: Eubiologics Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>SK Bio wins WHO prequalification for typhoid conjugate vaccine</title>
      <description>
        <![CDATA[SK Bioscience Co. Ltd. of Seongnam-si, South Korea, gained the World Health Organization’s (WHO) prequalification certification for typhoid conjugate vaccine, Skytyphoid (NBP-618), on Feb. 23. Skytyphoid conjugates a polysaccharide of typhoid bacteria, which serves as an antigen, to a diphtheria toxin protein called diphtheria toxoid that acts as a carrier.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706130</guid>
      <pubDate>Tue, 27 Feb 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/706130-sk-bio-wins-who-prequalification-for-typhoid-conjugate-vaccine</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/SKYTyphoid.webp?t=1708984079" type="image/jpeg" medium="image" fileSize="105173">
        <media:title type="plain">Skytyphoid</media:title>
        <media:description type="plain">Credit: SK Bioscience Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>SK Bio wins WHO prequalification for typhoid conjugate vaccine</title>
      <description>
        <![CDATA[SK Bioscience Co. Ltd. of Seongnam-si, South Korea, gained the World Health Organization’s (WHO) prequalification certification for typhoid conjugate vaccine, Skytyphoid (NBP-618), on Feb. 23. Skytyphoid conjugates a polysaccharide of typhoid bacteria, which serves as an antigen, to a diphtheria toxin protein called diphtheria toxoid that acts as a carrier.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706099</guid>
      <pubDate>Mon, 26 Feb 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/706099-sk-bio-wins-who-prequalification-for-typhoid-conjugate-vaccine</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/SKYTyphoid.webp?t=1708984079" type="image/jpeg" medium="image" fileSize="105173">
        <media:title type="plain">Skytyphoid</media:title>
        <media:description type="plain">Credit: SK Bioscience Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Breakthrough approval of malaria vaccine expected to close supply gap</title>
      <description>
        <![CDATA[It is not the first malaria vaccine, but R21, recommended for use by the World Health Organization in October, is the first that can be manufactured at modest cost and the sort of scale needed for widespread prevention of the killer disease in Africa.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704185</guid>
      <pubDate>Thu, 28 Dec 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704185-breakthrough-approval-of-malaria-vaccine-expected-to-close-supply-gap</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Top-Trends-Firsts.webp?t=1702938582" type="image/jpeg" medium="image" fileSize="88375">
        <media:title type="plain">Top Trends Firsts, finish line flag</media:title>
      </media:content>
    </item>
    <item>
      <title>Celebrating progress: The impact and challenges of the R21 malaria vaccine</title>
      <description>
        <![CDATA[The World Health Organization recently endorsed an economical malaria vaccine with a 75% effectiveness rate, which costs less than half of the initial vaccine (RTS,S/AS01) created two years ago. The new vaccine, R21/Matrix-M, developed by the University of Oxford and the Serum Institute of India, marks a significant milestone after decades of scientific research.]]>
      </description>
      <guid>http://www.bioworld.com/articles/702106</guid>
      <pubDate>Fri, 20 Oct 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/702106-celebrating-progress-the-impact-and-challenges-of-the-r21-malaria-vaccine</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Clinical-trial-syringe-and-vial.webp?t=1588960019" type="image/png" medium="image" fileSize="366118">
        <media:title type="plain">Syringe and vial</media:title>
      </media:content>
    </item>
    <item>
      <title>Post-pandemic COVID-19 era focuses on boosters, new strains</title>
      <description>
        <![CDATA[The official end of the COVID-19 public health emergency in the U.S. in May did not mark the end of interest and investment in the area. In the shifting landscape, attention has pivoted to new markets, emerging strains, boosters, and the commercialization and distribution of COVID-19 vaccines and therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/701950</guid>
      <pubDate>Tue, 17 Oct 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701950-post-pandemic-covid-19-era-focuses-on-boosters-new-strains</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Coronavirus-gray-and-white.webp?t=1672954760" type="image/png" medium="image" fileSize="212641">
        <media:title type="plain">Coronavirus gray and white</media:title>
      </media:content>
    </item>
    <item>
      <title>SK Bioscience strives for ‘equal access’ to Korean COVID-19 vaccine with WHO approval</title>
      <description>
        <![CDATA[The World Health Organization (WHO) recently gave an emergency use listing for SK Bioscience Ltd.’s COVID-19 vaccine called Skycovione, a self-assembled nanoparticle vaccine that targets the SARS-CoV-2 spike protein.]]>
      </description>
      <guid>http://www.bioworld.com/articles/698401</guid>
      <pubDate>Tue, 27 Jun 2023 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/698401-sk-bioscience-strives-for-equal-access-to-korean-covid-19-vaccine-with-who-approval</link>
    </item>
    <item>
      <title>WHO pushes for more access to COVID-19 drugs</title>
      <description>
        <![CDATA[As country after country downshifts out of pandemic mode, the need for affordable COVID-19 therapies continues, especially in middle-income countries that are not included in current voluntary licensing arrangements. To meet that need, the WHO is calling on manufacturers of those drugs to extend the geographic scope of their licensing agreements to allow competition and price reductions. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/696000</guid>
      <pubDate>Wed, 12 Apr 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/696000-who-pushes-for-more-access-to-covid-19-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Virus-and-drug-illustration.webp?t=1637179016" type="image/png" medium="image" fileSize="294622">
        <media:title type="plain">Virus and drug illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>WHO pushes for more access to COVID-19 drugs</title>
      <description>
        <![CDATA[As country after country downshifts out of pandemic mode, the need for affordable COVID-19 therapies continues, especially in middle-income countries that are not included in current voluntary licensing arrangements. To meet that need, the World Health Organization (WHO) is calling on manufacturers of those drugs to extend the geographic scope of their licensing agreements to allow competition and price reductions so the treatments can be used where they’re needed most.]]>
      </description>
      <guid>http://www.bioworld.com/articles/695962</guid>
      <pubDate>Tue, 11 Apr 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/695962-who-pushes-for-more-access-to-covid-19-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Virus-and-drug-illustration.webp?t=1637179016" type="image/png" medium="image" fileSize="294622">
        <media:title type="plain">Virus and drug illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>India drug regulations under the scanner again after fresh WHO alert on contaminated cough syrup</title>
      <description>
        <![CDATA[India’s drug regulatory system is under the lens again after the World Health Organization’s (WHO) latest medical product alert on two substandard cough syrups manufactured in the country.]]>
      </description>
      <guid>http://www.bioworld.com/articles/693806</guid>
      <pubDate>Tue, 31 Jan 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/693806-india-drug-regulations-under-the-scanner-again-after-fresh-who-alert-on-contaminated-cough-syrup</link>
    </item>
  </channel>
</rss>
